Aquilanti Elisa, Barkho Sulyman, Bozinov Vincent, Kageler Lauren, Garrity-Janger Max, Mesleh Michael F, Horner Steven, Ranaghan Matthew J, Meyerson Matthew
Division of Neuro Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02215, United States.
Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States.
ACS Chem Biol. 2025 Jul 18;20(7):1707-1714. doi: 10.1021/acschembio.5c00244. Epub 2025 Jun 10.
Telomerase reverse transcriptase is a ribonucleoprotein complex that maintains telomere length in rapidly dividing cells, thus enabling cellular immortality. Despite being recognized as an important cancer target for decades, no small molecule telomerase inhibitors have been approved as anticancer therapeutics to date. Several limitations, including the absence of high-throughput screening tools, have posed challenges to the telomerase drug discovery field. Here, we describe a high-throughput, fluorescently coupled screening method employing a chemically modified reporter nucleotide. We utilize the telomerase as a surrogate model as it shares a high degree of active site homology with the human enzyme. We piloted this tool by screening a chemical library of ∼3600 nucleoside mimetics to demonstrate excellent assay quality, and identified 2 compounds with inhibitory activity that were further validated in a direct enzymatic assay. Our work introduces a method that has the potential to uncover novel telomerase inhibitors for further drug discovery efforts.
端粒酶逆转录酶是一种核糖核蛋白复合体,它能维持快速分裂细胞中的端粒长度,从而使细胞实现永生。尽管几十年来一直被认为是重要的癌症靶点,但迄今为止还没有小分子端粒酶抑制剂被批准作为抗癌治疗药物。包括缺乏高通量筛选工具在内的几个限制因素给端粒酶药物研发领域带来了挑战。在此,我们描述了一种采用化学修饰报告核苷酸的高通量荧光偶联筛选方法。我们将端粒酶用作替代模型,因为它与人类酶具有高度的活性位点同源性。我们通过筛选一个约3600种核苷类似物的化学文库来试用此工具,以证明其出色的检测质量,并鉴定出2种具有抑制活性的化合物,这些化合物在直接酶促测定中得到了进一步验证。我们的工作引入了一种有潜力发现新型端粒酶抑制剂以推动进一步药物研发的方法。